Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Receivables (2016 - 2025)

Historic Receivables for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $195.7 million.

  • Haemonetics' Receivables fell 766.32% to $195.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $195.7 million, marking a year-over-year decrease of 766.32%. This contributed to the annual value of $202.7 million for FY2025, which is 189.05% down from last year.
  • According to the latest figures from Q4 2025, Haemonetics' Receivables is $195.7 million, which was down 766.32% from $207.1 million recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Receivables peaked at $213.5 million during Q3 2024, and registered a low of $132.4 million during Q2 2021.
  • For the 5-year period, Haemonetics' Receivables averaged around $182.1 million, with its median value being $183.4 million (2022).
  • As far as peak fluctuations go, Haemonetics' Receivables crashed by 2223.88% in 2021, and later skyrocketed by 2457.1% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' Receivables stood at $145.7 million in 2021, then rose by 28.82% to $187.7 million in 2022, then increased by 12.74% to $211.6 million in 2023, then increased by 0.16% to $211.9 million in 2024, then dropped by 7.66% to $195.7 million in 2025.
  • Its Receivables was $195.7 million in Q4 2025, compared to $207.1 million in Q3 2025 and $200.8 million in Q2 2025.